FluoroPharma Medical is a biopharmaceutical company engaged in the discovery and development of proprietary positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Currently, the company is advancing two such product candidates in clinical trials – including CardioPET and BFPet – which have been specially designed to rapidly target myocardial cells. Upon commercialization, these innovative products are expected to enable more accurate, early diagnosis of CAD, effectively facilitating improved treatment options and better patient outcomes.
The market potential for a more effective diagnostic tool for CAD is expansive. According to a report by the Centers for Disease Control and Prevention, heart disease accounts for approximately 610,000 deaths in the United States each year, making it the country’s leading cause of death. Among these fatalities, approximately 47 percent occur as a result of heart attacks outside of hospitals, suggesting that many people with CAD don’t receive proper diagnosis. FluoroPharma is addressing this issue by developing molecular imaging as a faster, more accurate approach to today’s standard test for diagnosing CAD.
CardioPET is designed to address the current limitations of CAD diagnostics. Upon commercialization, CardioPET is expected to be the first commercially-available fatty acid analog marker in the U.S. and Europe, giving FluoroPharma a noteworthy strategic advantage in the substantial diagnostic markets of the two regions. Unlike currently available tools, a traceable fatty acid analog marker will enable improved evaluation of cardiac blood flow and the dietary preference of the cardiac muscle under stress and at rest, clearly indicating the metabolic state of the heart and providing a more comprehensive assessment of CAD.
“We are encouraged by our progress to date, and believe that CardioPET potentially signals a compelling new direction for PET cardiac imaging at a time when healthcare professionals around the world could benefit from novel diagnostic imaging that expand and improve their diagnostic capabilities,” Thijs Spoor, chairman and chief executive officer of FluoroPharma, stated in a news release.
According to its most recent update, the company has completed enrollment for its phase II clinical trial of CardioPET for the assessment of CAD. This study, which is designed to assess the safety and diagnostic performance of FluoroPharma’s innovative agent, marks a significant step in the continued development of CardioPET. For prospective shareholders, the company’s sustained progress toward the commercialization of its promising development pipeline, in addition to the considerable marketability of its proprietary diagnostic tools, could foreshadow an opportunity for FluoroPharma to achieve sustainable returns in the months to come.
For more information, visit www.fluoropharma.com
